无创正压通气联合辛伐他汀治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的效果观察

摘要

Objective To investigate the clinical effects and safety of the noninvasive positive pressure ventilation (NIPPV) combined with Simvastatin in the treatment of COPD with type Ⅱ respiratory failure.Methods 158 COPD patients with type Ⅱ respiratory failure patients of the third hospital of Nanhai District in Foshan City from January 2011 to April 2012 were divided into two groups, 79 patients in the control group were treated by the conventional drugs and NIPPV, and 53 patients in the observation group were added the simvastatin on the basis of the control group.And then the two sets of clinical efficacy and blood gas were compared.Results The total effective rate of the observation group was 94.94%, and the control group was 82.28%, the difference was statistically significant between two groups (P < 0.05), after 12 weeks, the FEV1/FVC and FEV1 percentage of predicted of two groups were improvement more.Indicators of lung function of the observation group improved more significantly than in the control group (P < 0.05).Conclusion NIPPV combined with Simvastatin treatment for COPD combined with type Ⅱ respiratory failure efficacy, safety and reliability, can significantly improve the patient's respiratory function, vigorously promote worthy of clinical application.%目的 探讨无创正压通气(NIPPV)联合辛伐他汀治疗慢性阻塞性肺疾病(COPD)合并Ⅱ型呼吸衰竭的临床疗效和安全性.方法 佛山市南海区第三人民医院2011年1月～2012年4月将158例COPD合并Ⅱ型呼吸衰竭患者分为两组,对照组79例给予常规药物综合治疗和NIPPV治疗；观察组79例则在对照组基础上给予辛伐他汀治疗,并观察两组患者治疗前后动脉血气指标变化和临床疗效.结果 观察组的总有效率为94.94％,对照组为82.28％,两组比较差异有统计学意义(P＜0.05),两组患者治疗12周后一秒用力呼气容积/用力肺活量(FEV1/FVC)和FEV1占最大预计值明显改善(P＜ 0.05)；观察组的肺功能指标均较对照组改善更明显(P＜0.05).结论 NIPPV联合辛伐他汀治疗COPD合并Ⅱ型呼吸衰竭临床疗效确切,安全可靠,并可有效地改善患者肺功能,值得临床大力推广应用.